Optomed Oyj
OMXH:OPTOMED
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.945
7.27
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one OPTOMED stock under the Base Case scenario is 5.584 EUR. Compared to the current market price of 3.955 EUR, Optomed Oyj is Undervalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Optomed Oyj
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for OPTOMED cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Optomed Oyj
Balance Sheet Decomposition
Optomed Oyj
Current Assets | 16.6m |
Cash & Short-Term Investments | 11m |
Receivables | 3m |
Other Current Assets | 2.7m |
Non-Current Assets | 15.6m |
PP&E | 1.6m |
Intangibles | 14m |
Other Non-Current Assets | 16k |
Current Liabilities | 5.1m |
Accounts Payable | 3.6m |
Short-Term Debt | 193k |
Other Current Liabilities | 1.3m |
Non-Current Liabilities | 2.5m |
Long-Term Debt | 2.3m |
Other Non-Current Liabilities | 253k |
Earnings Waterfall
Optomed Oyj
Revenue
|
13.6m
EUR
|
Cost of Revenue
|
-4.8m
EUR
|
Gross Profit
|
8.8m
EUR
|
Operating Expenses
|
-14.6m
EUR
|
Operating Income
|
-5.8m
EUR
|
Other Expenses
|
-212k
EUR
|
Net Income
|
-6m
EUR
|
Free Cash Flow Analysis
Optomed Oyj
EUR | |
Free Cash Flow | EUR |
Optomed announced its Q1 results, highlighting FDA clearance for its Aurora AEYE-DS handheld camera. This AI-powered device achieves high efficacy and promises growth in the U.S. market. Despite the FDA milestone, revenue declined by 4.4% due to lagging software and flat device segments. The company is transitioning to a recurring revenue model with monthly subscriptions, boosting long-term prospects. Cash flow was slightly negative, and gross margins dipped due to strategic shifts. The firm is optimistic about future U.S. sales and Chinese market reinvention through a joint venture.
What is Earnings Call?
OPTOMED Profitability Score
Profitability Due Diligence
Optomed Oyj's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Optomed Oyj's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
OPTOMED Solvency Score
Solvency Due Diligence
Optomed Oyj's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
Optomed Oyj's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OPTOMED Price Targets Summary
Optomed Oyj
According to Wall Street analysts, the average 1-year price target for OPTOMED is 5.738 EUR with a low forecast of 5.05 EUR and a high forecast of 7.35 EUR.
Dividends
Current shareholder yield for OPTOMED is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Optomed Oyj engages in the provision of handheld fundus cameras and eye-screening solutions. The company is headquartered in Oulu, Oulun and currently employs 115 full-time employees. The company went IPO on 2019-12-09. The Group's Parent Company, Optomed Oyj, is responsible for, among other things, the management of the Group as well as finance and accounting functions, human resources, legal affairs and corporate communication. The Group's business is managed through two reportable segments: Devices and Software. The Devices segment develops, commercializes and manufactures easy-to-use and affordable handheld fundus cameras. The Software segment develops and sells screening software for diabetic retinopathy and cancer screening for healthcare organizations. The Optomed Group consists of the parent company Optomed Oyj and four subsidiaries in Finland, China, the USA and Hong Kong.
Officers
The intrinsic value of one OPTOMED stock under the Base Case scenario is 5.584 EUR.
Compared to the current market price of 3.955 EUR, Optomed Oyj is Undervalued by 29%.